Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Study of Axitinib and Temsirolimus in Solid Tumors
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 13
- Registration Number
- NCT01529138
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Phase II Study of Alternating Sunitinib and Temsirolimus
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT01517243
- Locations
- 🇺🇸
University of Vermont, Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 47
- Registration Number
- NCT01460979
- Locations
- 🇩🇪
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Gießen-Marburg, Standort Marburg, Marburg, Hessen, Germany
Temsirolimus In Phase 0
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT01417065
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01403415
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸C S Mott Children's Hospital, Ann Arbor, Michigan, United States
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 137
- Registration Number
- NCT01396408
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT01392183
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- Conditions
- Refractory Marginal Zone LymphomaRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaRecurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRecurrent Waldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01381692
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 33
- Registration Number
- NCT01378377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT01375829
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.